Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Equity Ratio (2022 - 2025)

Atara Biotherapeutics' Equity Ratio history spans 4 years, with the latest figure at 1.9 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 113.38% year-over-year to 1.9; the TTM value through Dec 2025 reached 1.9, down 113.38%, while the annual FY2025 figure was 1.9, 113.38% down from the prior year.
  • Equity Ratio reached 1.9 in Q4 2025 per ATRA's latest filing, down from 1.21 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.6 in Q4 2023 to a low of 1.9 in Q4 2025.
  • Average Equity Ratio over 4 years is 0.34, with a median of 0.43 recorded in 2024.
  • Peak YoY movement for Equity Ratio: skyrocketed 78.21% in 2023, then tumbled 3225.27% in 2024.
  • A 4-year view of Equity Ratio shows it stood at 0.34 in 2022, then surged by 78.21% to 0.6 in 2023, then crashed by 248.72% to 0.89 in 2024, then tumbled by 113.38% to 1.9 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Equity Ratio are 1.9 (Q4 2025), 1.21 (Q3 2025), and 0.95 (Q2 2025).